The goal of cancer pharmacogenomics is to obtain benefit from personalized approaches of cancer treatment and prevention. Recent advances in genomic research have shed light on the crucial role of genetic variants, mainly involving genes encoding drug-metabolizing enzymes, drug transporters and targets, in driving different treatment responses among individuals, in terms of therapeutic efficacy and safety. Although a considerable amount of new targeted agents have been designed based on a finely understanding of molecular alterations in cancer, a wide gap between pharmacogenomic knowledge and clinical application still persists. This review focuses on the relevance of mutational analyses in predicting individual response to antitumor therapy, in order to improve the translational impact of genetic information on clinical practice.
INTRODUCTION
Pharmacogenetics was first designated as a scientific matter in 1959 1 to investigate the unequal response to the same treatments by different patients in terms of beneficial effects, clinical efficacy and adverse reactions. Recently, in line with the increasing use of functional genomics in the clinical medicine during the post-genomic era, 'pharmacogenetics' was changed into 'pharmacogenomics', but both terms can be interchangeably used. 2 The purpose of this emerging field is to understand how genetic variants of drug-metabolizing enzymes, transporters and proteins involved in mechanisms of action of specific drugs, may influence their therapeutic effect. On the other hand, prediction of clinical response and potential drug-related toxicities is essential in managing the relevant costs of treating cancer, in particular with biomolecular drugs, and accounts for the great interest in studying genetic variants of specific genes. 3 The genomic sequencing of several human cancers has recently provided defined series of somatic gene mutations, 4,5 including single-nucleotide polymorphisms, namely single DNA base changes in a defined position, haplotypes as alleles at different loci together inherited, microsatellites as segments of DNA containing repeated sequences up to 6 bp, insertions and/or deletions as mutations resulting from addition/loss of DNA segments, copy number variations as gain and loss of large chunks of DNA producing an abnormal number of copies of one or more sections of DNA, aneuploidy as an irregular number of chromosomes with structural abnormality, and loss of heterozygosity that includes the defective function of a gene for which the other allele was already inactivated. Among these, single-nucleotide polymorphisms appear the most frequent and can be ordered in a singlenucleotide polymorphism map to be used in single patients to obtain genetic informations suggesting appropriate treatments producing expected clinical response.
Here, we report the most relevant applications of mutational analysis in selecting tailored anti-cancer treatments for solid tumors, also based on our own experience in specific tumors.
PHARMACOGENOMICS AND CANCER
Tumor progression is strongly associated with the activity of cell membrane receptors and their intracellular signal transduction pathways, which regulate several cell functions including proliferation, apoptosis, motility, adhesion and angiogenesis. Recent studies have emphasized the role of single-nucleotide polymorphisms, 6 mutations 6 and copy number variations 7 in different genes involved in the abnormal growth of cancer cells. In this context, based on the major role of the epidermal growth factor receptor (EGFR) in the pathogenesis of a number of solid tumors, 8 the transcriptional factors of EGFR pathway are regarded as putative targets of anti-cancer treatments.
EGFR is a 170 kDa transmembrane glycoprotein belonging to the ErbB family, which includes four members: the EGFR, also known as ErbB-1/HER1, ErbB-2/Neu/HER2, ErbB-3/HER3 and ErbB-4/HER4. 8 All these proteins show a similar less conserved ligandbinding extracellular domain, a single transmembrane domain, and a highly conserved intracellular domain with tyrosine kinase (TK) activity. 9 The key event leading to ErbB receptor activation includes the binding of a growth factor to the extracellular domain, resulting in the formation of receptor homo-or hetero-dimers. Subsequent molecular events mediate activation of the intrinsic TK domain, which in turn triggers several downstream pathways, such as ras/ raf/mitogen-activated ERK kinase (MEK)/mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways 10 ( Figure 1 ), driving many biological processes such as cell differentiation, cell cycle progression, cell invasivity, apoptosis and angiogenesis. 9, 11 Thus, overexpression of EGFR is believed to have a critical role in tumor progression, 8, 9, 11 and the molecular approaches inhibiting this pathway are apparently successful in treating several cancers.
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Inhibitors of proteins encoded by the majority of overexpressed or mutated genes along the EGFR signaling pathway have been recently reviewed by McDermott et al.
3 For instance, EGFR mutations are reported in non-small cell lung cancer (NSCLC) whereas the gene overexpression occurs in glioblastoma. 12 Furthermore, ErbB-2/Neu/HER2 is overexpressed in breast 13 and gastric cancer, 14 K-ras (Kirsten rat sarcoma viral oncogene homolog) and BRAF mutations in colorectal cancer, 15 specific BRAF mutations recur in melanoma, 16 phosphatidylinositol 3-kinase mutations in colorectal, breast, gastric cancers and glioblastoma. 17 Finally, increased activation of mammalian target of rapamycin has been detected in renal cell carcinoma. 18 However, despite the wide number of mutations occurring in cancer genetics, only a few have been approved by the Food and Drug Administration (FDA) as molecular targets and predictive biomarkers for new tailored therapeutics (Table 1) . They include mutation of EGFR (OMIM #131550) and echinoderm microtubuleassociated protein-like 4 (EML4)--ALK in NSCLC, 19, 20 c-KIT (OMIM #164920) and platelet-derived growth factor receptor alpha (PDGFRa, OMIM #173490) in gastrointestinal stromal tumors (GISTs), 21 K-ras (OMIM #190070) in metastatic colorectal cancer (mCRC), 22, 23 and BRAF (OMIM #164757) in melanoma, 24 whereas the clinical usefulness of other promising genetic markers is currently under investigation (www.mycancergenome.com). 25 Our institutions (Department of Internal Medicine and Clinical Oncology, University of Bari, Italy, and Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele Pisana, Rome, Italy) routinely perform pharmacogenetic screenings for K-ras, BRAF, c-KIT, PDGFRa and EGFR. Table 2 shows mutation frequency of the above-mentioned genes obtained, up to date, from overall studies performed in our laboratory.
However, despite accumulating data on pharmacogenomics in oncology, there are very few conclusive studies providing specific clinical recommendations. Indeed, several clinicians are still unfamiliar with pharmacogenetic tests because of the lack of standardized guidelines filling the gap between pharmacogenomic knowledge and its clinical application. Only recently, a specific program aimed at conciliating pharmacogenomic informations to daily practice has been adopted by the Clinical Pharmacogenomics Implementation Consortium of the National Institutes of Health's Pharmacogenomics Research Network (http://www.pgrn.org). 26 Pharmacogenomic-based studies of anti-cancer agents are also complicated by the genetic heterogeneity of a cancer population and the occurrence of additional somatic mutations within tumor, thus emphasizing the importance of microdissection from tissue samples as these populations need to be individually procured for analysis. These observations underline the need to develop and apply high-throughput molecular-profiling techniques to analyze and validate potential biomarkers.
EGFR MUTATIONAL STATUS AND TREATMENT OF NSCLC
NSCLC is the most common type of lung cancer and a major cause of death from cancer. 27 For early-stage disease, surgery, even when followed by adjuvant chemotherapy, 28 offers the best opportunity for long-term survival. In patients with advanced NSCLC, the use of cytotoxic chemotherapy is associated with a response rate of 20--35% and a median survival time of 10--12 months. 29 Despite the improvement of the overall survival provided by the use of multilinear therapeutic regimens, advanced NSCLC is currently considered incurable and the only new options available are based on mutational studies of EGFR. In fact, inhibition of EGFR with either Gefitinib or Erlotinib appears effective in restraining the tumor growth and both of drugs were approved as first-line treatment of NSCLC. 30 These small molecules directly inhibit TK phosphorylation by interfering with either the adenosine triphosphate and/or the enzyme substrate-binding sites, thus suppressing the EGFR pathway. 11 Several trials have confirmed their clinical efficacy 31, 32 as second-or third-line therapy in advanced NSCLC and, based on longer progression-free survival (PFS) and lower toxicity obtained with these drugs as compared with standard chemotherapy, recent studies support their use also as first-line treatment. 33, 34 However, clinical responses to both of TK Inhibitors (TKIs) differ among NSCLC patients. Increasing evidence indicates that therapeutic response to TKIs is associated to aberrant EGFR TK signaling because of activating mutations in the TK domain (exons 18 through 21). 35--39 Major oncogenic mutations include deletion of a leucine--arginine--glutamate--alanine motif (E746_A750del) within exon 19 and thymine-to-guanine transversion in exon 21 leading to an arginine-for-leucine substitution at amino acid 858 (L858R). 38 Figure 2 shows location and frequency of somatic mutations in the TK domain of EGFR (Genbank accession no. NC-000007) reported in NSCLC, 38 and an electropherogram, obtained in our laboratory, showing the most recurrent somatic change L858R.
After TKI-based treatment, NSCLC patients harboring such mutations show higher response rate and improved survival times compared with EGFR wild-type (WT) patients. 40 Clinical Figure 1 . EGFR signaling pathway. The EGFR is activated by its appropriate ligand with autophoshorylation of SH2 binding domains that recruit small adaptor proteins SOS and Grb2. The GrB2/SOS complex stimulates activation of K-ras by binding to guanosine triphosphate (GTP), thus transducing the activation signal to the nucleus. Guanosine triphosphatase hydrolysis of guanosine triphosphate to guanosine diphosphate (GDP) leads to inactivation of Ras. In particular, guanosine triphosphate-bound Ras activates RAF/mitogen-activated ERK kinase/ERK pathway, which regulates cell proliferation and motility, and PI3K/PTEN/AKT/mTOR cascade, involved in anti-apoptotic responses. Mutational change of K-ras leads to a permanent activated status that triggers the signal transduction pathway regardless upstream EGFR activation or inhibition through anti-EGFR mAbs. AKT, protein kinase B-alpha; EGFR, epidermal growth factor receptor; ERK, extracellular signalregulated kinase; GRB2, growth factor receptor-bound protein 2; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog; RAS, Kirsten murine sarcoma virus 2; RAF, V-Raf murine sarcoma viral oncogene homolog B1; SOS, GTPases son of sevenless; TK, tyrosine kinase. studies indicated that the higher response rates achieved in Asiatic never-smoker female patients with lung adenocarcinoma treated with EGFR TKIs were related to the high incidence in these populations of mutations in the TK domain of EGFR. 31, 41, 42 Thus, clustering of mutations within specific regions of the EGFR TK domain makes feasible the development of rapid diagnostic tests to guide the clinical use of both Gefitinib and Erlotinib.
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A number of patients treated with EGFR TKIs, however, develop resistance to both of drugs. It has been reported that about half of these patients may express an additional EGFR mutation, namely the substitution of threonine with methionine at codon 790 in the TK domain (T790M) 43, 44 leading to a steric interference with the binding of TKIs that restores the adenosine triphosphate affinity. 44 This mutation mainly occurs in relapsed tumors after initial response to the TKI-based therapy, whereas its recurrence, as germ-line mutation, in a family with inherited susceptibility to lung cancer suggests the pivotal role of the mutation in tumor growth. 45 Moreover, the identification of the T790M mutation in circulating cancer cells of patients showing tumor progression during treatment with TKIs further supports the use of non-invasive serial monitoring of emerging EGFR mutations during TKI-based therapy. 46 These findings suggest that prospective validation of EGFR TK domain mutations as predictors of responsiveness to TKIs improves benefit from either Gefitinib or Erlotinib in terms of PFS and overall response rate, although no study has shown so far a real advantage in overall survival. 41 The use of Gefitinib in patients with NSCLC harboring EGFR mutations was thus approved in July 2009 by European Medicines Agency, while in 2010, the Italian Association of Medical Oncology, in collaboration with the Italian Society of Anatomic Pathology and Diagnostic Cytopathology, published the recommendations for mutational analysis of EGFR in lung Abbreviations: EGFR, epidermal growth factor receptor; GIST, gastrointestinal stromal tumor; mCRC, metastatic colorectal cancer; NSCLC, non-small cell lung cancer; PDGFRa, platelet-derived growth factor receptor a. All molecular analyses are performed using direct sequence analysis (ABI 3130 Genetic Analyzer-Applied Biosystems) and all detected sequence variants are confirmed in duplicate experiments, using independentlyextracted DNA samples.
carcinoma. 47 This is crucial for a correct clinical use of TKIs because it helps in anticipating both responsiveness and occurrence of resistance, although this latter could be mediated by other mechanisms including c-MET amplification 48 and HER2, HER3, mitogen-activated protein kinase and AKT1 activation.
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EML4--ALK REARRANGEMENTS IN NSCLC
The ALK gene (OMIM #105590) encodes a TK receptor and is involved in formation of many fusion proteins. 50, 51 The fusion of ALK with EML4 (OMIM #607442), on the short arm of chromosome 2, was reported in approximately 4% of never-or light-smoker patients with NSCLC 52 and studies involving East Asian patients reported that up to 13% of lung tumors may harbor EML4--ALK fusions.
53--59
The EML4--ALK encodes a transforming fusion protein that mediates the ligand-independent oligomerization of ALK resulting in constitutive ALK kinase activation. 56, 60, 61 Apart from rare exceptions, EML4--ALK rearrangements are mutually exclusive of EGFR and K-ras mutations, 54, 55, 58, 62 as patients with EML4--ALK do not benefit from EGFR TKIs' therapy, similarly to those lacking EGFR mutations. 58 Nevertheless, cancers holding ALK fusions are sensitive to specific ALK inhibitors. Most of them are currently under investigation 63 whereas only Crizotinib (PF-02341066) has been approved for clinical use. 62, 64 Early results from a phase I study emphasized the therapeutic efficacy of Crizotinib, because an objective response rate of 56% and a median PFS of 9.2 months were reached in a cohort of 105 EML4--ALK-positive NSCLC patients. 63, 64 These data led to open a phase-3 registration trial (http://www.cancer.gov/clinicaltrials/search/view?cdrid ¼ 649260 &version ¼ healthprofessional#StudyIdInfo_CDR0000649260) and, in August 2011, the FDA approved Crizotinib for the treatment of patients with locally advanced or metastatic NSCLC with ALK mutation. Recently, two studies reported that patients who relapsed after Crizotinib may hold two secondary resistance mutations within the ALK TK domain, 65, 66 namely the C1156Y substitution and the gatekeeper mutation L1196M. 65, 66 To date, more than nine different variants of the EML4--ALK fusion gene have been identified. 67 This supports the importance of using highly sensitive rapid amplification of cDNA ends-coupled PCR sequencing methods for identifying patients for targeted therapies. 68 
K-RAS MUTATIONAL ANALYSIS AND TREATMENT OF mCRC
Although a number of therapeutic approaches have been introduced in the clinical practice over the last few years, mCRC represents a major challenge for clinical oncology. EGFR-directed monoclonal antibodies (anti-EGFR MoAbs), namely Cetuximab and Panitumumab have entered in clinic based on the predominant expression (up to 80%) of EGFR in colorectal tumors. 69 Cetuximab is an immunoglobulin G1 (IgG1) chimeric mouse/human MoAb that, after binding to EGFR, promotes its internalization resulting in a selective inhibition of downstream signal transduction. 70 Since 2004, Cetuximab has been approved, in combination with Irinotecan, for the treatment of Irinotecan-refractory EGFR-expressing (EGFR þ ) patients, or as monotherapy in patients intolerant to Irinotecan. 71 Panitumumab, a fully human IgG2 MoAb, also directed to EGFR, was introduced in 2006 for treatment of EGFR þ -metastatic-mCRCs in clinical progression. 72 Although both of these MoAbs bind EGFR, their mechanism of action slightly differs. In fact, unlike IgG2 MoAbs, those belonging to the IgG1 isotype can activate the complement and induce antibody-dependent cellular cytotoxicity, although this has not been proven for Cetuximab. 73 The response variability shown by mCRC to EGFR-targeting agents gained attention on the putative mechanisms underlying primary resistance to these agents. 74 Although the high EGFR expression is a reliable predictor of response, 75 other genetic factors such as K-ras mutations, may drive unresponsiveness of patients 76 with poor prognosis.
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K-ras belongs to a proto-oncogene family comprising other two genes, namely H-ras (Harvey rat sarcoma viral oncogene homolog), and N-ras (neuroblastoma RAS viral (v-ras) oncogene homolog), positioned on unrelated chromosomes. 78 When bound by guanosine triphosphate, K-ras protein is active, whereas it becomes inactive as guanosine triphosphate is converted to guanosine diphosphate. Active K-ras interferes with several kinase effectors such as RAF, extracellular signal-regulated kinase and phosphatidylinositol 3-kinase, thus regulating a variety of cellular processes. 78 As K-ras is a downstream effector of EGFR, in case of K-ras-activating mutations, EGFR signaling is maintained activated in a ligand-independent manner and the upstream inhibition of EGFR by MoAbs results ineffective (Figure 2) .
Activating mutations of K-ras are observed in approximately 40% of sporadic colorectal cancers, 78 and up to 90% include G-to-A transitions 79 and G-to-T transversions 80 in codons 12 and 13. Less frequently, mutations occur in codons 61, 63 and 146, and, rarely, in the presence of concomitant mutations. 81--83 Figure 3 shows the frequency of K-ras (GenBank accession no. NC_000012) mutations, represented as electropherograms obtained from mCRC samples in our laboratory. 84--88 Therefore, a correct assessment of K-ras mutational status is required for the selection of mCRC patients who can benefit from anti-EGFR MoAb-based treatment, as pointed by a number of clinical trials. 76, 88, 89 The phase III CRYSTAL study compared efficacy of FOLFIRI (5-fluorouracil, folinic acid/Irinotecan) plus Cetuximab protocol to FOLFIRI alone as first-line treatment in 540 patients with EGFR þ -mCRC stratificated for K-ras mutational status WT. 89 Approximately 35% of patients were found to hold K-ras mutations and, retrospectively, the addition of Cetuximab to FOLFIRI significantly improved PFS in K-ras WT patients with respect to the K-ras mutants. Similarly, Cetuximab also leads to significant increase in overall response rate in K-ras WT patients (43% vs 59%, P ¼ 0.0025), whereas no improvement was observed in the mutant population (40% vs 36%, P ¼ 0.46). 88 In the phase II OPUS study, 233 tumor specimens were assessed for K-ras mutations, in order to evaluate the efficacy of adding Cetuximab to the FOLFOX protocol in the first-line treatment of mCRC. 89 Again, addition of the MoAb prolongated PFS only in the subset of WT patients (58%), as compared with mutants (42%). 89 In the multicenter randomized phase III trial evaluating efficacy of Panitumumab in combination with chemotherapy (PRIME), mCRC patients with no prior chemotherapy, Eastern Cooperative Oncology Group performance status of 0--2, and available tissue Figure 3 . Frequency of K-ras mutations in metastatic colorectal cancer patients. Data extracted from Normanno et al., 84 Rascal II study 85 and Neumann et al. 86 Other rare mutations are available on the Catalogue Of Somatic Mutation In Cancer 87 (COSMIC, Sanger Institute) (http:// www.sanger.ac.uk/genetics/CGP/cosmic/). All sequence analyses were performed in our laboratory.
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for biomarker testing were randomly assigned 1:1 to receive Panitumumab plus infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) vs FOLFOX4 alone, in order to evaluate the efficacy and safety of Panitumumab as initial treatment for mCRC. 90 This study demonstrated that Panitumumab---FOLFOX4 was well tolerated and significantly improved PFS in patients with WT K-ras tumors, emphasizing the importance of K-ras testing for patients with mCRC. 90 However, a minor subset of patients with WT K-ras do not benefit from anti-EGFR MoAb treatment, because of either alteration of other genes enrolled in the EGFR signaling pathway, such as BRAF 91 and PIK3CA 92 or overexpression of phosphatase and tensin homolog protein 93 and EGFR ligands. 96 Approximately 60--70% of these tumors develop in stomach, followed by small intestine (30%), esophagus or large intestine and rectum 96 (o5%), whereas they rarely occur outside the gastrointestinal tract. 96 It is estimated that 480% of patients with GIST carry a gain-offunction somatic mutation in c-KIT, 97 whereas 5--7% hold mutation in PDGFRa.
98 c-KIT and PDGFRa mutations are mutually exclusive and drive the tumorigenesis of GISTs, as they underlay structural changes of the relative receptors, resulting in a constitutive persistent autoactivation. 97, 98 Four hot spots have been identified in c-KIT sequence, 97 as represented in Figure 4 . Up to 65% of c-KIT mutations affect the juxtamembraneous domain (exon 11), an autoinhibitory region that maintains the inactivated conformation in the absence of the KIT ligand, 97 whereas other mutations rarely occur in the extracellular region (exon 9, 10--15%) 99 or in the TK domain (exons 13 and 17, o1%).
100
PDGFRa mutations are prevalently found within the TK domain (exon 18, up to 90%) and, at a lesser extent, in the juxtamembraneous domain (exon 12) or in the first part of the TK domain (exon 14) (Figure 4 ). 98 Discovery of these mutations fueled the development and clinical use of selective TKIs. Imatinib, a TKI successfully adopted in chronic myeloid leukemia, 101 was approved in 2002 for treatment of unresectable and/or metastatic GIST 102 and several studies have confirmed its efficacy also as adjuvant therapy of these tumors, because of the high homology between the adenosine triphosphate-binding pocket of c-kit and Bcr--Abl. The pivotal trial Z9001, 103 indeed, showed that patients receiving the TKI in adjuvant (400 mg per day Â 12 months) had a significant improvement in PFS with respect to the placebo group. 103 Therefore, in 2008 the FDA approved Imatinib for adjuvant therapy of resected adult GIST, whereas additional ongoing trials are aimed at defining the therapeutic value of Imatinib in the neoadjuvant setting. 104 Binding of Imatinib to the adenosine triphosphate-binding pocket of c-KIT and PDGFRa mediates a competitive inhibition of the enzymatic activity of these receptors, 102 thus driving antiproliferative and pro-apoptotic effects on GISTs cells. Affinity of Imatinib depends, in part, on the type of mutation, and on the codons affected, thus emphasizing the role of mutational analysis in identifying GIST genotypes that are likely to be scarcely responsive to Imatinib. 105, 106 Several studies suggest that tumors with mutations in the TK domain (exons 13 and 17) are not effectively inhibited by Imatinib, but these types of mutations occur in o1%. Fortunately, most of GISTs carry mutations in the juxtamembraneous domain (exon 11), so that they are intrinsically higher sensitive to Imatinib than those with an exon 9 mutation or without c-KIT mutations at all. 105 In addition, based on recent studies demonstrating that another TKI, namely Sunitinib, is effective in GIST with exon 9 mutation, 107 the FDA approved Sunitinib malate for the treatment of patients with GIST in clinical progression or intolerant to Imatinib. On the other hand, PDGFRa mutations, and particularly the most frequent point mutation D842V in exon 18, may lead to a primary resistance to Imatinib. 108 Moreover, with longer duration of TKI-based treatment, the risk of resistance to therapy increases, also because of the potential acquisition of secondary mutations in the kinase domain. 109 These evidences underline that molecular subclassification of GISTs, even at the time of progression during the first-line treatment, provides valuable information for patient management. 110 BRAF MUTATIONAL ANALYSIS IN MELANOMA Malignant skin melanoma is one of the most chemoresistant human neoplasias and its incidence has risen faster than other solid tumors over the past 60 years (http://seer.cancer.gov/). Early-stage patients can be successfully treated with surgical resection, whereas those in advanced stage have o5% of survival rate within 5 years.
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Approximately 70--80% of acquired melanocytic nevi 112 and 40--60% of malignant melanoma 113 express somatic mutations of BRAF, particularly the oncogenic-activating V600E mutation. 113--121 Thus, many selective inhibitors of mutant BRAF were developed and are currently under preclinical and clinical investigation (http://clinicaltrials.gov).
Vemurafenib, a potent inhibitor of the V600E BRAF kinase activity, was the first agent showing clinical advantages in treating melanoma. 120 In a single phase I trial, 11 out of 16 BRAF V600E mutation-bearing patients showed considerable tumor response to Vemurafenib, whereas no clinical response was observed in patients with WT BRAF tumor. 120 In the phase II trial, BRIM-2 enrolling 132 patients with advanced melanoma who had received one prior therapy, the overall response rate was 53%, with a complete response rate equal to 5% and a PFS of 6.7 months. 122 In tumors expressing the BRAF V600E mutation, Vemurafenib lowered levels of phosphorylated extracellular signal-regulated kinase, which is associated with clinical response. 123 Furthermore, Vemurafenib was recently tested in a phase III randomized trial against Dacarbazine in 675 never-treated melanoma patients harboring the V600E mutation. 119 It showed a significant overall survival advantage as single agent against Dacarbazine 119 (48% vs 5%, respectively), thus prompting the recent FDA approval for the treatment of advanced melanoma with mutant BRAF.
As in other cancers, however, mechanisms of resistance must be considered. Resistance to Vemurafenib may arise within 8 months 119, 120 and depend on the reactivation of the mitogenactivated protein kinase pathway 124, 125 or, alternatively, on the acquisition of additional activating mutation in the mitogenactivated ERK kinase protein. 126 Once again, this emphasizes the clinical impact of genotyping tumors to select the best patients for the most appropriate treatment.
CONCLUSIONS AND FUTURE PERSPECTIVE
Genomic heterogeneity among tumors inevitably causes differences between unrelated patients in terms of responsiveness to the same treatment. Pharmacogenomics has made significant progress in recent years and traced a new face of cancer therapy.
In the light of the close link between drug mechanism of action, genomics and biology, the goal of cancer pharmacogenomics is to obtain the highest benefits from personalized anti-cancer approaches in both cancer treatment and prevention. Moreover, this may also be relevant in cost--benefit analysis in applying the genetic diagnostic tests. A number of genetic markers have been identified so far, and even if many of them are not candidate for routinary use, the analysis of tumor-biopsy samples for a subgroup of key mutations has been introduced as a mandatory test in the clinical practice.
The FDA has recently addressed the integration of pharmacogenomic studies into drug development and medical practice, and approved the adoption of novel drugs, including Gefitinib or Erlotinib as first-line therapy of NSCLC, Cetuximab for the treatment of EGFR-expressing mCRC and Imatinib as adjuvant therapy of GIST.
To optimize pharmacogenomic studies, clinicians must routinely collect biospecimens by using standardized protocols, and obtain high-quality samples for any subsequent genomic analyses. The importance of pharmacogenomics, indeed, is also related to the identification of mutations accounting for the drug resistance acquired by some patients during treatment.
At present, this effect may be explained as product of secondary mutations acquired by cancer cells during the treatment. Recent findings, however, emphasize the existence within tumors of a subset of stem cell-like cells, namely cancer stem cells, endowed with high tumor-regenerative capacity and drug resistance. 127--129 The cancer stem cell hypothesis may thus provide an alternative explanation for the failure of targeted approaches, because these treatments are able to ablate proliferating cancer cells whereas favoring emergence of a small pool of quiescent cancer stem cells that hold resistant mutations responsible for tumor relapse.
The application of gene sequencing strategies to predict the efficacy of novel anti-cancer drugs recently benefits from a new tool allowing high-throughput DNA sequencing. This method, called next-generation sequencing, uses high number of parallel sequence reactions to read millions of bases in a single run. 130 Nextgeneration sequencing has the potential to rapidly detect, at single base pair resolution, all somatic mutations, rearrangements, small insertion/deletions and copy number variations in an entire genome. 131 Another important application of next-generation sequencing is represented by the so-called 'deep sequencing', an approach allowing an extensive reading coverage of targeted genomic regions during the same sequencing process. 132, 133 This methodology holds many considerable advantages, including (i) extension of pharmacogenomics studies to entire genetic pathways instead of a single gene; 133--135 (ii) identification of secondary mutations responsible for drug resistance; 136--138 (iii) selection of somatic mutations in small cell subclones within a large component of normal cells; 131 and (iv) recovery of short DNA fragments from formalin-fixed, and paraffin-embedded samples. 130, 139 Based on increasingly available scientific data, the 'nextgeneration sequencing' techniques, although at the beginning of their development, can represent the definitive tools for introducing pharmacogenetic markers in the common clinical practice, enabling us to look forward to an exciting future of this developing science.
